- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04920344
Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy
Study Overview
Status
Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
Intervention / Treatment
- Procedure: Transoral Surgery
- Procedure: Incisional Tumor Biopsy
- Other: Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment
- Other: MD Anderson Dysphagia Index
- Other: University of Washington Quality of Life Questionnaire
- Other: Euro-QOL 5 dimension scale questionnaire
- Diagnostic test: Modified barium swallow (MBS) evaluation with aspiration-penetration scale
- Radiation: External Beam Radiation Therapy
- Drug: Cisplatin
Detailed Description
PRIMARY OBJECTIVE:
I. To measure swallowing function and disease specific quality of life of patients with oropharyngeal cancer treated with transoral surgery and reduced intensity adjuvant therapy.
SECONDARY OBJECTIVES:
I. To examine kinetics of circulating tumor deoxyribonucleic acid (DNA) in patients treated with transoral surgery.
II. To estimate local control, progression free and overall survival using transoral surgery and reduced intensity adjuvant therapy.
OUTLINE: Based on pathologic findings after standard of care transoral surgery, patients are assigned to 1 of 3 groups.
GROUP I (LOW RISK): Patients whose small tumor was removed completely and have only one lymph node involved will undergo clinical observation.
GROUP II (MEDIUM RISK): Patients whose tumor was removed completely but has certain features that make it more likely to come back such as growth around the nerves or into the vessels, or has more than one lymph nodes involved, will undergo external body radiation therapy (EBRT) for 5 weeks in the absence of disease progression or unacceptable toxicity.
GROUP III (HIGH RISK): Patients whose tumor has a "positive margin", which means the tumor could not be removed with healthy tissue around it or tumor grows significantly outside the lymph node will undergo EBRT for 6 weeks and receive cisplatin intravenously (IV) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
New Brunswick, New Jersey, United States, 08903
- RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick
-
Newark, New Jersey, United States, 07103
- Rutgers Cancer Institute of New Jersey at University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically proven squamous cell carcinoma of the oropharynx
- Clinical stage T1-2, N0-N3, M0 by American Joint Committee on Cancer (AJCC) 8 criteria
- Must have tumors deemed surgically resectable with acceptable morbidity
- Estimated life expectancy of at least 12 weeks
- Must give informed consent
- Must have Eastern Cooperative Oncology Group (ECOG) performance status =< 3
- Must have detectable circulating HPV DNA levels
- Platelets >= 100,000/ul
- Absolute neutrophil count (ANC) >= 1,500/ul
- Hemoglobin > 8 g/dl (use of transfusion to achieve this is acceptable)
- Total bilirubin < 2 X institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 3 X institutional ULN
- Serum creatinine < 2 x institutional ULN or creatinine clearance > 50 ml/min as determined by 24 hour collection or estimated by Cockcroft-Gault formula
- Negative pregnancy test, if applicable
Exclusion Criteria:
- Patients may not have received previous therapy for their head and neck squamous cell carcinoma (SCC), including chemotherapy, radiation therapy, or surgery beyond biopsy
Second primary malignancy. Exceptions are:
- Patient had a second primary malignancy but has been treated and disease free for at least 3 years
- In situ carcinoma (e.g. in situ carcinoma of the cervix)
- Non-melanomatous carcinoma of the skin
- Patients with metastatic disease beyond the neck will be excluded
- Serious concomitant systemic disorders (including active infections) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator
- Age < 18 years
- Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: CD4 count is > 499/cu mm and their viral load is < 50 copies/ml. Use of highly active antiretroviral therapy (HAART) is allowed
Grade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events [CTCAE], version [v.] 5)
- Serum calcium (ionized or adjusted for albumin) < 7 mg/dl (1.75 mmol/L) or > 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels
- Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels
- Potassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels
- Sodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels
- Women who are pregnant, due to the teratogenic effects of radiation therapy and chemotherapy on the unborn fetus. Women of childbearing age must agree to undergo a pregnancy test prior to therapy and to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Tumor deemed unresectable with acceptable morbidity:
- Tumors > 4 cm in size (T3 or higher)
- Tumors of the base of tongue < 4 cm but with deep invasion of tongue musculature placing hypoglossal nerve or both lingual arteries at risk
- Significant extension into hypopharynx
- Extension into soft palate beyond 1/3 of the width
- Clinically extensive extranodal extension (ENE) e.g. radiologic evidence of invasion of carotid artery, gross extension into sternocleidomastoid muscle or deep neck muscles.
Lymph nodes larger than 6 cm without clinical ENE will be allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: GROUP I - Low Risk Recurrence (transoral surgery, clinical observation))
After standard of care transoral surgery, patients whose small tumor was removed completely and have only one lymph node involved will undergo clinical observation.
|
Patients will undergo transoral surgery
Other Names:
Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
Other Names:
MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects.
It was originally designed for head and neck cancer patients.
The total score ranges from 20 to 100 with the higher score indicating higher level of function.
Other Names:
University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
Other Names:
A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
Other Names:
The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms. The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration.
Other Names:
|
Experimental: GROUP II - Medium Risk Recurrence (transoral surgery, EBRT 50Gy)
Patients whose tumor was removed completely but has certain features that make it more likely to come back such as growth around the nerves or into the vessels, or has more than one lymph nodes involved, will undergo external body radiation therapy (EBRT) RT 50Gy for 5 weeks in the absence of disease progression or unacceptable toxicity.
|
Patients will undergo transoral surgery
Other Names:
Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
Other Names:
MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects.
It was originally designed for head and neck cancer patients.
The total score ranges from 20 to 100 with the higher score indicating higher level of function.
Other Names:
University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
Other Names:
A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
Other Names:
The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms. The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration.
Other Names:
Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
Other Names:
|
Experimental: GROUP III - High Risk Recurrence (transoral surgery, EBRT 60Gy, cisplatin 30 mg/m2)
Patients whose tumor has a "positive margin", which means the tumor could not be removed with healthy tissue around it or tumor grows significantly outside the lymph node will undergo EBRT RT 60 Gy for 6 weeks and receive cisplatin intravenously (IV) weekly 30mg/m2 for 6 weeks in the absence of disease progression or unacceptable toxicity.
|
Patients will undergo transoral surgery
Other Names:
Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
Other Names:
MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects.
It was originally designed for head and neck cancer patients.
The total score ranges from 20 to 100 with the higher score indicating higher level of function.
Other Names:
University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
Other Names:
A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
Other Names:
The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms. The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration.
Other Names:
Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
Other Names:
Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MD Anderson Dysphagia Index (MDADI)
Time Frame: At baseline.
|
MDADI is a 20 item quality of life instrument specifically focusing on swallowing aspects.
It was originally designed for head and neck cancer patients and has been widely used and validated in this population.
The total score ranges from 20 to 100 with the higher score indicating higher level of function.
|
At baseline.
|
MD Anderson Dysphagia Index (MDADI)
Time Frame: At 24 weeks post completion of therapy.
|
MDADI is a 20 item quality of life instrument specifically focusing on swallowing aspects.
It was originally designed for head and neck cancer patients and has been widely used and validated in this population.
The total score ranges from 20 to 100 with the higher score indicating higher level of function.
|
At 24 weeks post completion of therapy.
|
MD Anderson Dysphagia Index (MDADI)
Time Frame: At 1 year post completion of therapy.
|
MDADI is a 20 item quality of life instrument specifically focusing on swallowing aspects.
It was originally designed for head and neck cancer patients and has been widely used and validated in this population.
The total score ranges from 20 to 100 with the higher score indicating higher level of function.
|
At 1 year post completion of therapy.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Locoregional control.
Time Frame: At 3 years post completion of therapy
|
Will be assessed using survival analysis (e.g., Kaplan-Meier method and Cox proportional hazards model).
|
At 3 years post completion of therapy
|
Disease free survival.
Time Frame: At 3 years post completion of therapy
|
Will be assessed using survival analysis (e.g., Kaplan-Meier method and Cox proportional hazards model).
|
At 3 years post completion of therapy
|
Progression free survival.
Time Frame: At 3 years post completion of therapy
|
Will be assessed using survival analysis (e.g., Kaplan-Meier method and Cox proportional hazards model).
|
At 3 years post completion of therapy
|
Overall survival.
Time Frame: At 3 years post completion of therapy
|
Will be assessed using survival analysis (e.g., Kaplan-Meier method and Cox proportional hazards model).
|
At 3 years post completion of therapy
|
University of Washington Quality of Life Questionnaire
Time Frame: At baseline, 24 weeks and 1 year post completion of therapy
|
University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
Scoring is scaled to so that a score of 0 represents the worst possible response, and a score of 100 represents the best possible response.
The higher the score - the better the outcome.
|
At baseline, 24 weeks and 1 year post completion of therapy
|
European Quality of Life Five Dimension Five Level Scale Questionnaire scores
Time Frame: At baseline, 24 weeks, and 1 year post completion of therapy
|
Euro-QOL 5 dimension scale is a generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer. Euro-QOL 5 dimension scale is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The answers can be converted into EQ-5D index an utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status). |
At baseline, 24 weeks, and 1 year post completion of therapy
|
Rate of gastrostomy tube dependence
Time Frame: At baseline, 24 weeks, and 1 year post completion of therapy
|
Percentage of patients requiring a gastrostomy tube after completion of therapy will be analyzed using generalized linear model (GLM) analysis.
|
At baseline, 24 weeks, and 1 year post completion of therapy
|
Penetration-Aspiration Score on Modified Barium Swallow examination
Time Frame: Baseline and 1 year post completion of therapy
|
Objective swallowing function assessment using modified barium swallow (MBS) evaluation with aspiration-penetration scale. The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration. The higher the score, the worse is the outcome. |
Baseline and 1 year post completion of therapy
|
Correlation of circulating tumor deoxyribonucleic acid (ctDNA) levels with known adverse pathological features
Time Frame: At baseline and at 4 weeks post-surgery
|
Correlation of ctDNA levels at baseline with known adverse pathological features such as, number of involved lymph nodes, extranodal extension and positive margins.
Will be analyzed using GLM analysis.
|
At baseline and at 4 weeks post-surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Matin Imanguli, MD, DDS, Rutgers Cancer Institute of New Jersey
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Carcinoma
- Oropharyngeal Neoplasms
- Antineoplastic Agents
- Cisplatin
Other Study ID Numbers
- 032008
- P30CA072720 (U.S. NIH Grant/Contract)
- Pro2020002824 (Other Identifier: Rutgers Cancer Institute of New Jersey)
- NCI-2021-03006 (Registry Identifier: NCI CTRP registry)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
-
Jonathan Schoenfeld, MD, MPHNaverisRecruitingHPV Positive Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterAstraZenecaTerminatedOropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive)...United States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive)... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IV Hypopharyngeal Carcinoma AJCC v8 | Stage IV Laryngeal Cancer... and other conditionsUnited States
-
Mayo ClinicRecruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal Human Papillomavirus-Positive Squamous...United States
-
Jonsson Comprehensive Cancer CenterEli Lilly and CompanyTerminatedClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage IV HPV-Mediated (p16-Positive)... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologySuspendedOropharyngeal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Basaloid Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Papillary Squamous Cell Carcinoma | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditionsUnited States, Canada
-
Mayo ClinicRecruitingOropharyngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative)... and other conditionsUnited States
Clinical Trials on Transoral Surgery
-
Saglik Bilimleri UniversitesiCompleted
-
Intuitive SurgicalCompletedOropharyngeal CancerUnited States
-
University of Alabama at BirminghamTerminatedObstructive Sleep Apnea Hypopnea Syndrome (OSAHS)United States
-
Katherine L FedderActive, not recruitingOropharyngeal Squamous Cell Carcinoma | Supraglottic Squamous Cell CarcinomaUnited States
-
Intuitive SurgicalCompletedObstructive Sleep ApneaKorea, Republic of
-
Hospices Civils de LyonCompletedSupraglottic Squamous Cell CarcinomaFrance
-
Lawson Health Research InstituteActive, not recruitingEarly-Stage Squamous Cell Carcinoma of the OropharynxCanada, Australia
-
Technical University of MunichCompletedRadiofrequency ResectionGermany
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Stanford UniversityTerminatedHypopharyngeal Neoplasms | Laryngeal Neoplasms | Head and Neck CancersUnited States